OncoMatch/Clinical Trials/NCT06500884
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Is NCT06500884 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Talquetamab and Prophylaxis A for relapse multiple myeloma.
Treatment: Talquetamab · Prophylaxis A · Prophylaxis B · Prophylaxis C — The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Must have received: immunomodulatory drug
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Must have received: anti-CD38 monoclonal antibody
triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Francisco · San Francisco, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Yale University School Of Medicine · New Haven, Connecticut
- Icahn School of Medicine at Mt. Sinai · New York, New York
- University of Rochester Medical Center · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify